Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

University of Florida · with National Institute on Drug Abuse (NIDA) · NCT04218409

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 21–45 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
45
US sites recruiting
1
Study start
September 2, 2021
Record last updated
January 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Being studied: OxyCODONE 5 mg Oral Tablet; Oxytocin nasal spray; Placebo Oxycodone; Placebo oxytocin; OxyCODONE 2.5 mg Oral Tablet

Conditions: Pain

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Individuals fluent in English will participate.
  • Must report recreational use of opioids.
  • Be within 20% of their ideal body weight.
  • Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  • Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  • Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.

Exclusion criteria

  • Significant current physical disease or major psychiatric disorder.
  • No self-reported current interest in drug abuse treatment.
  • Women who are pregnant or nursing.
  • Any comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.
  • Any conditions that preclude safety in the MRI scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is MRI safe), and claustrophobia.

Recruiting US locations

Study contacts (from the official record)

  • Lauren Nieder · 352-294-1067 · lauren.nieder@ufl.edu
All healthy volunteers studies in Florida →
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A… (NCT04218409) | Bored Studies